A Prospective Study to Evaluate Alterations in Molecular Biomarkers in HER2 Neu Positive Metastatic Breast Cancer Together With Assessment of Trastuzumab Use Beyond Progression After Initial Response to Trastuzumab-taxane Based Treatment
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Taxanes
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms SHERsig
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 03 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Oct 2013 Planned end date changed from 1 Apr 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.